TherapeuticsMD Files 8-K on Financials
Ticker: TXMD · Form: 8-K · Filed: Nov 13, 2025 · CIK: 25743
Sentiment: neutral
Topics: financial-condition, results-of-operations, disclosure
Related Tickers: TXMD
TL;DR
TXMD filed an 8-K on Nov 12, 2025, covering financial results and operations.
AI Summary
On November 12, 2025, TherapeuticsMD, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as AMHN, Inc., is incorporated in Nevada and headquartered in Boca Raton, Florida.
Why It Matters
This 8-K filing provides crucial updates on TherapeuticsMD's financial performance and operational status, which are essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- TherapeuticsMD, Inc. (company) — Registrant
- November 12, 2025 (date) — Date of earliest event reported
- AMHN, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- Boca Raton, Florida (location) — Business address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on TherapeuticsMD, Inc.'s results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements and exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing occurred on November 12, 2025.
What is the Commission File Number for TherapeuticsMD, Inc.?
The Commission File Number for TherapeuticsMD, Inc. is 001-00100.
In which state is TherapeuticsMD, Inc. incorporated?
TherapeuticsMD, Inc. is incorporated in Nevada.
What are the business and mailing addresses for TherapeuticsMD, Inc.?
The business and mailing addresses for TherapeuticsMD, Inc. are both listed as 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL 33431.
Filing Stats: 591 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-11-12 20:54:31
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 per share TXMD The Nasdaq Stock Mar
Filing Documents
- ea0265416-8k_therape.htm (8-K) — 28KB
- ea026541601ex99-1_therape.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-109479.txt ( ) — 213KB
- txmd-20251112.xsd (EX-101.SCH) — 3KB
- txmd-20251112_lab.xml (EX-101.LAB) — 33KB
- txmd-20251112_pre.xml (EX-101.PRE) — 22KB
- ea0265416-8k_therape_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. The information provided in Item 7.01 of this Current Report on Form 8-K is incorporated in this Item 2.02 by reference.
01
Item 7.01 Regulation FD Disclosure. On November 12, 2025, TherapeuticsMD, Inc., a Nevada corporation (the "Company"), issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and the information contained in Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing. The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Index Exhibit No. Description 99.1 Press Release from TherapeuticsMD, Inc., dated November 12, 2025, entitled "TherapeuticsMD Announces Third Quarter 2025 Financial Results." 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 12, 2025 THERAPEUTICSMD, INC. /s/ Marlan Walker Marlan Walker Chief Executive Officer 2